The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
The cash and debt free consideration value is €370 million.
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Subscribe To Our Newsletter & Stay Updated
